|
1）Murakami M, Taketomi Y, Miki Y, et al. Recent progress in phospholipase A2 research: from cells to animals to humans. Prog. Lipid Res. 2011; 50: 152-92
|
|
|
|
|
2）Li P, Oh da Y, Bandyopadhyay G, et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015; 21: 239-47
|
|
|
|
|
3）Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995; 83: 803-12
|
|
|
|
|
4）Fujimori K, Yano M, Ueno T. Synergistic suppression of early phase of adipogenesis by microsomal PGE synthase-1 (PTGES1)-produced PGE2 and aldo-keto reductase 1B3-produced PGF2α. PLoS One. 2012; 7: e44698
|
|
|
|
|
|
5）Vegiopoulos A, Muller-Decker K, Strzoda D, et al. Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science. 2010; 328: 1158-61
|
|
|
|
|
|
6）Ii H, Yokoyama N, Yoshida S, et al. Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A2-knockout mice. PLoS One. 2009; 4: e8089
|
|
|
|
|
|
7）Ishihara K, Miyazaki A, Nabe T, et al. Group IVA phospholipase A2 participates in the progression of hepatic fibrosis. FASEB J. 2012; 26: 4111-21
|
|
|
|
|
|
8）Hadad N, Burgazliev O, Elgazar-Carmon V, et al. Induction of cytosolic phospholipase A2α is required for adipose neutrophil infiltration and hepatic insulin resistance early in the course of high-fat feeding. Diabetes. 2013; 62: 3053-63
|
|
|
|
|
|
9）Fischer J, Lefevre C, Morava E, et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet. 2007; 39: 28-30
|
|
|
|
|
|
10）Haemmerle G, Lass A, Zimmermman R, et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science. 2006; 312: 734-7
|
|
|
|
|
|
11）Haemmerle G, Moustafa T, Woelkart G, et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med. 2011; 17: 1076-85
|
|
|
|
|
|
12）Tang T, Abbott MJ, Ahmadian M, et al. Desnutrin/ATGL activates PPARδ to promote mitochondrial function for insulin secretion in islet β cells. Cell Metab. 2013; 18: 883-95
|
|
|
|
|
|
13）Ahmadian M, Abbott MJ, Tang T, et al. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab. 2011; 13: 739-48
|
|
|
|
|
|
14）Ahmadian M, Duncan RE, Varady KA, et al. Adipose overexpression of desnutrin promotes fatty acid use and attenuates diet-induced obesity. Diabetes. 2009; 58: 855-66
|
|
|
|
|
|
15）Nomura DK, Morrison BE, Blankman JL, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 2011; 334: 809-13
|
|
|
|
|
|
16）Schlager S, Goeritzer M, Jandl K, et al. Adipose triglyceride lipase acts on neutrophil lipid droplets to regulate substrate availability for lipid mediator synthesis. J Leukoc Biol. 2015; 98: 837-50
|
|
|
|
|
|
17）Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40: 1461-5
|
|
|
|
|
|
18）Huang Y, He S, Li JZ, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A. 2010; 107: 7892-7
|
|
|
|
|
|
19）Li JZ, Hung Y, Karaman R, et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest. 2012; 122: 4130-44
|
|
|
|
|
|
20）Smagris E, BasuRay S, Li J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology. 2015; 61: 108-18
|
|
|
|
|
|
21）Kumari M, Schoiswohl G, Chitraju C, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012; 15: 691-702
|
|
|
|
|
|
22）Yoda E, Hachisu K, Taketomi Y, et al. Mitochondrial dysfunction and reduced prostaglandin synthesis in skeletal muscle of Group VIB Ca2＋-independent phospholipase A2γ-deficient mice. J Lipid Res. 2010; 51: 3003-15
|
|
|
|
|
|
23）Mancuso DJ, Sims HF, Han X, et al. Genetic ablation of calcium-independent phospholipase A2γ leads to alterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetic phenotype. J Biol Chem. 2007; 282: 34611-22
|
|
|
|
|
|
24）Mancuso DJ, Sims HF, Yang K, et al. Genetic ablation of calcium-independent phospholipase A2γ prevents obesity and insulin resistance during high fat feeding by mitochondrial uncoupling and increased adipocyte fatty acid oxidation. J Biol Chem. 2010; 285: 36495-510
|
|
|
|
|
|
25）Bao S, Song H, Wohltmann M, et al. Insulin secretory responses and phospholipid composition of pancreatic islets from mice that do not express group VIA phospholipase A2 and effects of metabolic stress on glucose homeostasis. J Biol Chem. 2006; 281: 20958-73
|
|
|
|
|
|
26）Lei X, Zhang S, Barbour SE, et al. Spontaneous development of endoplasmic reticulum stress that can lead to diabetes mellitus is associated with higher calcium-independent phospholipase A2 expression: a role for regulation by SREBP-1. J Biol Chem. 2010; 285: 6693-705
|
|
|
|
|
|
27）Bao S, Jacobson DA, Wohltmann M, et al. Glucose homeostasis, insulin secretion, and islet phospholipids in mice that overexpress iPLA2β in pancreatic β-cells and in iPLA2β-null mice. Am J Physiol Endocrinol Metab. 2008; 294: E217-29
|
|
|
|
|
|
28）Ramanadham S, Yarasheski KE, Silva MJ, et al. Age-related changes in bone morphology are accelerated in group VIA phospholipase A2 (iPLA2β)-null mice. Am J Psthol. 2008; 172: 868-81
|
|
|
|
|
|
29）Murakami M, Sato H, Miki Y, et al. A new era of secreted phospholipase A2. J Lipid Res. 2015; 56: 1248-61
|
|
|
|
|
|
30）Labonte ED, Kirby RJ, Schildmeyer NM, et al. Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia. Diabetes. 2006; 55: 935-41
|
|
|
|
|
|
31）Hui, DY. Phospholipase A2 enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol. 2012; 23: 235-40
|
|
|
|
|
|
32）Hui DY, Cope MJ, Labonte ED, et al. The phospholipase A2 inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice. Br J Pharmacol. 2009; 157: 1263-9
|
|
|
|
|
|
33）Wilson SG, Adam G, Langdown M, et al. Linkage and potential association of obesity-related phenotypes with two genes on chromosome 12q24 in a female dizygous twin cohort. Eur J Hum Genet. 2006; 14: 340-8
|
|
|
|
|
|
34）Sato H, Isogai Y, Masuda S, et al. Physiological roles of group X-secreted phospholipase A2 in reproduction, gastrointestinal phospholipid digestion, and neuronal function. J Biol Chem. 2011; 286: 11632-48
|
|
|
|
|
|
35）Li X, Shridas P, Forrest K, et al. Group X secretory phospholipase A2 negatively regulates adipogenesis in murine models. FASEB J. 2010; 24: 4313-24
|
|
|
|
|
|
36）Shridas P, Zahoor L, Forrest KJ, et al. Group X secretory phospholipase A2 regulates insulin secretion through a cyclooxygenase-2-dependent mechanism. J Biol Chem. 2014; 289: 27410-7
|
|
|
|
|
|
37）Sato H, Taketomi Y, Ushida A, et al. The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity. Cell Metab. 2014; 20: 119-32
|
|
|
|
|
|
38）Wootton PT, Arora NL, Drenos F, et al. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study. Hum Mol Genet. 2007; 16: 1437-44
|
|
|
|
|
|
39）Boilard E, Lai Y, Larabee K, et al. A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. EMBO Mol Med. 2010; 2: 172-87
|
|
|
|
|
|
40）Giannattasio G, Fujioka D, Xing W, et al. Group V secretory phospholipase A2 reveals its role in house dust mite-induced allergic pulmonary inflammation by regulation of dendritic cell function. J Immunol. 2010; 185: 4430-8
|
|
|
|
|
|
41）Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011; 11: 738-49
|
|
|
|
|
|
42）Jaworski K, Ahmadian M, Duncan RE, et al. AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat Med. 2009; 15: 159-68
|
|
|
|
|
|
43）Uyama T, Kawai K, Kono N, et al. Interaction of phospholipase A/acyltransferase-3 with Pex19p: a possible involvement in the down-regulation of peroxisomes. J Biol Chem. 2015; 290: 17520-34
|
|
|
|
|
|
44）Long JZ, Cisar JS, Milliken D, et al. Metabolomics annotates ABHD3 as a physiologic regulator of medium-chain phospholipids. Nat Chem Biol. 2011; 7: 763-5
|
|
|
|
|
|
45）Blankman JL, Long JZ, Trauger SA, et al. ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proc Natl Acad Sci U S A. 2013; 110: 1500-5
|
|
|
|
|
|
46）Kamat SS, Camara K, Parsons WH, et al. Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. Nat Chem Biol. 2015; 11: 164-71
|
|
|
|
|
|
47）Thomas G, Betters JL, Lord CC, et al. The serine hydrolase ABHD6 is a critical regulator of the metabolic syndrome. Cell Rep. 2013; 5: 508-20
|
|
|
|
|
|
48）Zhao S, Mugabo Y, Iglesias J, et al. α/β-Hydrolase domain-6-accessible monoacylglycerol controls glucose-stimulated insulin secretion. Cell Metab. 2014; 19: 993-1007
|
|
|
|
|